Latest News and Press Releases
Want to stay updated on the latest news?
-
MedVi Examined (URGENT REPORT 2026) Is It Legit? Benefits, Safety, Complaints, and Customer Feedback
Find out more about MEDVi and how it works exactly! New York City, NY, Feb. 08, 2026 (GLOBE NEWSWIRE) -- Weight management has long been a challenge in the United States and rising obesity...
-
MEDVI Quad prescription information updated as consumer interest in prescription erectile dysfunction treatment access through telehealth grows
-
MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs
Analysis examines MEDVi's compounded GLP-1 semaglutide telehealth model, FDA compounding framework, and prescription weight loss trends for 2026.
-
New York City, NY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- As demand for GLP-1 weight loss medications continues to rise in 2026, many consumers are actively searching for a reliable GLP-1 supplier...
-
FDA approves first oral GLP-1 for weight loss as patients evaluate Wegovy, Zepbound, and compounded options. MEDVi lists programs from $179.
-
New York City, NY, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Intro As medical weight loss continues to evolve in 2026, the landscape of GLP-1 therapies has reached a pivotal moment with expanded...
-
FDA approves oral Wegovy pill Dec 2025. Analysis compares FDA-approved injectable, oral, and compounded semaglutide access pathways for 2026.
-
MEDVi lists compounded GLP-1 injections at $179 first month, $299 refills as 100,000+ patients seek affordable semaglutide ahead of 2026 New Year.
-
New York City, NY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- What Is MEDVi? – Inside the Doctor-Led GLP-1 Program Revolutionizing Modern Weight Management In an era where effective weight loss solutions...
-
Los Angeles, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional before...